A relation between pyridoxine and convulsive phenomena has been established over several years (Snyderman, Holt, Carretero, and Jacobs, 1953; Molony and Parmelee, 1954; Adams, Bessey, Bussey, and Hansen, 1954; May, 1954; Coursin, 1954 Coursin, , 1955 . This led to a search for evidence of pyridoxine deficiency among children with cryptogenic epilepsy. Soon patients were discovered who, though receiving a normal amount of pyridoxine, stopped convulsing when given supplements of this vitamin and relapsed when these were withdrawn
reported an apparent association of the form of childhood epilepsy known as infantile spasms ('lightning fits', 'massive myoclonic epilepsy', West's syndrome), with pyridoxine deficiency. The five patients he studied excreted more than the normal amount of xanthurenic acid following the administration of tryptophan, a finding in accord with pyridoxine deficiency, and on administration of this vitamin, 'a definite decrease in the frequency of their convulsions and an improvement in mental status was observed'. This was further investigated by Bower (1961) and Bower and Hughes (1961) who reported on the tryptophan load test in a small group of normal children; in a group of patients with infantile spasms (subdivided into those associated with some other disorder, 'symptomatic' and those without, 'cryptogenic'); and in a small group which included, without differentiation, children with other forms of epilepsy and mental deficiency. The results of this preliminary study suggested that half the children with cryptogenic infantile spasms Received March 31, 1966. excreted more than the normal amount of xanthurenic acid, whereas all those in the symptomatic group were normal in this respect. Treatment with ACTH or corticosteroids, the favoured therapy, resulted in a reduction in the excretion of xanthurenic acid in all cases. Because of the relation of the biochemical abnormality to pyridoxine deficiency, the effect of giving this vitamin was examined but the clinical response in the few patients studied at that time was equivocal.
Following these preliminary results a more detailed study of tryptophan metabolism in this group of patients has been made and is the subject of the present report. A greater number of patients with infantile spasms has been studied in order to see whether the difference between the symptomatic and cryptogenic groups is real. Patients with other forms of epilepsy have been studied, in case the biochemical abnormality is related to the convulsions themselves, rather than to their several causes. The results of these two studies allow the evaluation of the tryptophan load test as a means of differentiating one aetiological group of spasms from another, and one clinical form of epilepsy from another. Since patients with infantile spasms are usually mentally retarded, a group of patients with mental retardation but without any evidence of epilepsy has been studied to examine the possibility that the biochemical abnormality is associated with mental subnormality rather than with epilepsy.
There is an apparent contradiction between the increase in xanthurenic acid excretion, indicating pyridoxine deficiency, and the failure of this vitamin to improve affected patients. Further evidence for the association of the biochemical defect with this vitamin has therefore been sought by studying several other pyridoxine-dependent metabolites of tryptophan. The value of the tryptophan load test in deciding between various forms of treatment and in determining their effectiveness will be considered in a later paper.
The present paper demonstrates that there is no difference in the frequency of abnormal tryptophan load tests between the symptomatic and cryptogenic Tables I to V , XA* = xanthurenic acid as determined by the ferric alum method; the remainder of the metabolites were determined after chromatographic separation, XA = xanthurenic acid, K = kynurenine, KA = kynurenic acid, 3-OH K = 3-hydroxykynurenine, 3-OH AA = 3-hydroxyanthranilic acid. health at the time, those who had had an infection having made a good recovery. Their ages ranged from 2 months to 5 years (Table I) .
CNS disorders without convulsions (Group 2). The details of these 20 patients (11 boys, 9 girls) are shown in Table II. Epilepsy-other than infantile spasms (Group 3).
(Henceforth called the epileptic group.) The details of these 46 patients (26 boys, 20 girls) are shown in Table III .
Healthy controls (Group 1). This group consists of
Infantile spasms-cryptogenic (Group 4). These 14 children (9 boys, 5 girls) in hospital for reasons other 27 patients (20 boys, 7 girls) had an uneventful delivery than epilepsy and dietary deficiency. They were in good and had developed normally until the onset of spasms, This preparation was usually tolerated, but in a few patients vomiting occurred and the dose had to be Infantile spasms-symptomatic (Group 5). In repeated after a few hours. In two patients a convulsion these 32 patients (25 boys, 7 girls) a definite or probable occurred 3 hours after the administration. As these cause for the spasms and mental subnormality was found. patients had previously had convulsions it is uncertain The criteria for diagnosis are discussed elsewhere whether tryptophan played any part in causing these (Jeavons and Bower, 1964) and the cerebral insults are attacks. listed, together with other details, in Table V. Xanthurenic acid was determined by its reaction with ferric alum (modification of Bessey et al., 1957) . In
Urine was collected for 6-hourly periods, 12 hours many cases simultaneous quantitative determinations before and 24 hours after an oral dose of L-tryptophan. were also made of xanthurenic acid, kynurenine, (The mixture of D-and L-isomers was not used since the kynurenic acid, 3-hydroxykynurenine, and semi-D-isomer is excreted unchanged or as the corresponding quantitative assessment of 3-hydroxyanthranilic acid, keto-acid.) following separation of these metabolites by two- The value for the 12-hour period before tryptophan loading was doubled and subtracted from the figure obtained for the 24-hour collection after loading. The resulting difference is the figure used in all subsequent discussion. The other metabolites were identified under ultraviolet light by their characteristic fluorescence. They were cut out, eluted, and determined by modifications of the methods described by Coppini, Benassi, and Montorsi (1959) and Brown (1957) . These will be the subject ofa separate communication where the differences between the results given by the two methods of determining xanthurenic acid will be discussed. Electroencephalograms have been quantitated using the scoring system described by Jeavons and Bower (1961) .
Results Excretion of xanthurenic acid by healthy controls. Table I shows that subjects who are regarded as normal excrete less than 3 mg. xanthurenic acid per day. Whether or not this represents the upper limit of normal is still undecided. The factors affecting the excretion of xanthurenic acid following a tryptophan load are still not fully elucidated. The excretion certainly depends upon the dose of tryptophan and, as yet, the amount of xanthurenic acid that would be excreted by a human subject suffering from a slight but significant deficiency of pyridoxine is not known. Some of our findings in fact suggest that there are factors other than a deficiency of pyridoxine, in its usual sense, affecting the excretion of xanthurenic acid.
Although the excretion of xanthurenic acid depends, at least in adult subjects, on the amount of tryptophan given (Hughes and Raine, 1966) , the evidence at present available suggests that this effect is not marked in children below the age of 4-5 years. Comparison of our findings with those previously published (Table VI) suggests that even with different dose schedules most authors find values for the excretion of xanthurenic acid of the same order as our own. In an earlier paper (Bower, 1961 ) the normal subjects and certain patients not suffering from infantile spasms were considered together as a control group, and none of these excreted more than 5 mg. xanthurenic acid. In the present study epileptic patients and those with other neurological disorders have not been included in the control group. None of the control group in the present study excreted more than 3 mg. per day, and this figure has therefore been used to divide normal from abnormal.
Excretion of xanthurenic acid by all clinical groups. The frequency with which the excretion of xanthurenic acid exceeded 3 mg. in 24 In each group there are a few results only slightly above 3 mg., the level at which the above analysis has been made. The greatest number of these borderline results is found in group 5 (infantile spasms of symptomatic origin), and it is of interest to consider the difference that would result if the results were analysed in terms of an upper limit of, say, 6 mg. The data have, therefore, been subjected to a similar analysis taking 6 mg., instead of 3 mg., as the dividing line for abnormal tests and the frequency of abnormal tests calculated. Although the latter is reduced in each clinical group (group 2, 25%; group 3, 33 %; group 4, 15%; group 5, 16%; group (4 + 5), 15%), the differences between any pair of groups remains insignificant. For example the probabilities by the x2 test that the differences could arise by chance are for groups 2 and 3, 0 8; for groups 4 and 5, 0 *75; for groups (4 + 5) and 3, 0 11; for groups (4 + 5) and 2, 0 75; and for groups 4 and 3, 0-15.
Two factors that may have further influenced these findings are a difference in age or sex distribution, and a difference in the incidence of anticonvulsant therapy within each clinical group. The mean and the range of ages in each group are: group 1, 2 months to 5 years, mean 20-5 months; group 2, 4 months to 5 5 years, mean 27 months; group 3, 3 weeks to 12 years 8 months, mean 27 months; group 4, 3 months to 2 years 2 months, mean 9 months; group 5, 2 months to 8 years 11 months, mean 11 months. Thus there are slight differences in the means of the clinical groups, but these are insufficient to have had a substantial effect on the proportion of abnormal results. There was no difference in the frequency of abnormal results in males and females. The effect of anticonvulsant therapy, which in this series of patients included phenobarbitone, sodium phenytoin, and primidone, is examined in Fig. 1 Excretion of metabolites other than xanthurenic acid. In Fig. 2 the excretion of xanthurenic acid, 3-hydroxykynurenine, kynurenic acid, and kynurenine are plotted, and 3-hydroxyanthranilic acid is shown either to be present or absent. All of these metabolites have been determined following paper chromatography. The patients have been divided initially on the basis of their xanthurenic acid excretion, determined by the simple ferric alum method without chromatographic purification. Those excreting less than 3 mg. by this method are marked by a dot, and those excreting more than this by a circle. A solid line marks the upper limit of those subjects excreting less than 3 mg. xanthurenic acid, and a dotted line the lower limit of those excreting more than 3 mg. xanthurenic acid. Thus an area is outlined in which the excretion of the other metabolites is not in accord with the excretion of xanthurenic acid. The determination of xanthurenic acid by the simple ferric alum method has been criticized, since the reaction is not very specific. It is interesting, therefore, to find that the excretion of xanthurenic acid following paper chromatography (Fig. 2 , column 1) is in complete accord with that by the simpler method. With the other metabolites, however, there is in each case some overlap. This is least for kynurenine, and slightly more for kynurenic acid and 3-hydroxyanthranilic acid, but in the case of 3-hydroxykynurenine the overlap is substantial. Thus, examination of the other metabolites usually reinforces the conclusion drawn from the determination of xanthurenic acid by the simple procedure. It is considered that, where the facilities for the more complex chromatographic determinations are not available, useful information can be obtained by using the ferric alum procedure alone.
EEG findings. In infantile spasms the EEG is always abnormal. The degree of abnormality in each record was quantitated by Dr. P. M. Jeavons using a scoring system previously described (Jeavons and Bower, 1961) . A score of 2-8 is labelled epileptic (i.e. non-hypsarrhythmic) and a score of 9-30 is hypsarrhythmic, the most abnormal EEG pattern in epilepsy. Table VIII shows that hypsarrhythmic records were found equally commonly in those patients with a normal and an abnormal xanthurenic acid excretion. In the epileptic group (group 3) there are more epileptic and fewer normal records in the patients with increased xanthurenic acid excretion than in those with a normal excretion. With this exception there is no evidence of a significant correlation between the EEG and the biochemical abnormalities. 10 had an abnormal xanthurenic acid excretion, whereas only 1 of 9 in the immunization group did so. This suggests a correlation between perinatal insult and abnormal xanthurenic acid excretion, but the fact that 7 of the 27 patients in the cryptogenic group, where no such insult was admitted, also had the biochemical abnormality renders the significance of the correlation extremely doubtful.
Discussion
The finding of abnormal xanthurenic acid excretion after tryptophan loading was reported in all of 5 cases of infantile spasms studied by Cochrane (1959) , in 3 of 4 patients studied by Jeune, Cotte, Hermier, Yasse, and Leriche (1959) , and in 7 of 10 patients studied by Segni and Gandullia (1962) . Hellstrom and Vassella (1962) studied 14 patients of whom 5 gave an abnormal result, but when 2 of these 5 were repeated, a normal result was obtained. Our own earlier work (Bower, 1961; Bower and Hughes, 1961) also showed a proportion of abnormal results in patients with infantile spasms.
More recently, patients with forms of epilepsy other than infantile spasms have been found to have abnormal xanthurenic acid excretion following a tryptophan load, notably 1 of 2 patients studied by Segni and Gandullia (1962) , 9 of 38 patients studied by Hottinger, Berger, and Krauthammer (1964) , and 26 of 43 patients with cryptogenic epilepsy studied by Hagberg, Hamfelt, and Hansson (1965) . Similar results have been reported by ourselves (Bower, Hughes, and Raine, 1965) .
The only study in which patients with chronic cerebral disorders but no epilepsy have been examined in this way is that of Hottinger et al. (1964) who found abnormal xanthurenic acid excretion in 5 of 35 subjects. Hagberg et al. (1965) have studied patients with progressive brain disorder, not all of whom had convulsions, but from their publication it is not possible to determine the frequency of abnormal tests in the latter group alone.
The results reported in the present study show that not only is there no correlation between the aetiological subgroup of infantile spasms or the clinical variety of epilepsy and the level of xanthurenic acid excretion, but the presence or absence of epilepsy itself seems unrelated to xanthurenic acid excretion. Before accepting such a conclusion, however, we should consider whether the xanthurenic acid excretion bears any relation to the EEG findings. If there is any correlation between childhood epilepsy and xanthurenic acid excretion, we should expect abnormal excretion to occur mainly in those patients with the more abnormal EEGs. No such correlation was found however, nor was there any with the degree of mental subnormality or with the associated disorders in the symptomatic group of infantile spasms.
Thus the tryptophan load test can provide no help in the differential diagnosis of cerebral disorders or of convulsive disorders. It may, however, provide an important part of the investigation of two rare conditions, namely a dietary deficiency of pyridoxine and pyridoxine dependency.
In view of the apparently obvious relationship of the increased xanthurenic acid excretion (in response to a tryptophan load) to pyridoxine deficiency, the effects of administering this vitamin have been particularly disappointing. Although in every case this biochemical abnormality has been corrected, there has been little or no clinical improvement in the subjects treated. It was therefore important to examine further the extent to which the biochemical abnormality in these subjects is related to pyridoxine.
To this end several other tryptophan metabolites dependent either directly or indirectly upon pyridoxine have been studied. These include kynurenine, kynurenic acid, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid, and their relation to the vitamin and to xanthurenic acid is shown in Fig. 3 . It can be seen that if the activity of the enzyme kynureninase, which is responsible for the conversion of 3-hydroxykynurenine to 3-hydroxyanthranilic acid and which is very dependent upon pyridoxine, is deficient, then 3-hydroxykynurenine and kynurenine will accumulate and the two products of side-reaction, kynurenic acid and xanthurenic acid, will be more prominent. Our present study shows that when the xanthurenic acid excretion is greater than normal, in many instances the excretion of the other four metabolites studied supports the belief that the over-all biochemical defect is associated with some aspect of pyridoxine utilization. The precise nature of this defect is still quite unknown, but the biochemical response to various forms of treatment is relevant to this question and this will be considered in a subsequent paper.
Summary
The tryptophan load test was applied to 139 children comprising the following clinical groups: healthy controls; children with chronic cerebral disorders unassociated with epilepsy; children with epilepsy other than infantile spasms; and children with infantile spasms, subdivided into cryptogenic and symptomatic groups. The excretion of xanthurenic acid, and in some cases of four other metabolites, was determined. Results were abnormal in about one-third of patients in each group. There was no correlation of abnormal results with the presumed aetiology, the degree of mental subnormality, or the severity of EEG abnormality, and the results appeared to be unaffected by anticonvulsant therapy. The excretion of metabolites other than xanthurenic acid supports the view that an abnormal result in these patients is related to a defect of pyridoxine utilization.
We have found the tryptophan load test to be of little value in the investigation of convulsive disorders in childhood.
